Kling Biotherapeutics doses first patient in advanced solid tumor trial
Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial…
September 29, 2022 - 2 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Removing binding sites for an oncogene can slow cancer cell growth, researchers say
Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers…
September 29, 2022 - 3 minutes
Positive results from study of drug to treat patients with breast cancer published
Results from a phase 1b study of a drug to treat patients with androgen receptor…
September 29, 2022 - 3 minutes
Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies
Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of…
September 28, 2022 - 2 minutes
Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors
Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A…
September 28, 2022 - 3 minutes
Cleara Biotech closes $2.5M seed financing round to progress senescence treatment
Cleara Biotech has closed a $2.5 million seed financing round that it will use for…
September 28, 2022 - 4 minutes
Bioheng Biotech has positive CAR-T cell therapy results published in academic journal
Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy…
September 27, 2022 - 3 minutes
Natural killer cells: a thriving frontier in allogeneic cell therapy
Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could…
September 27, 2022 - 6 minutes
Angel Pharma announces approval of IND application for clinical trial of mupadolimab
Approval of an investigational new drug (IND) application for mupadolimab has been granted by the…
September 27, 2022 - 2 minutes
Sponsored
by Biognosys
Using the power of proteomics to predict immunotherapy responses in melanoma and beyond
Next-generation proteomics has a vital role to play in the search for new biomarkers of…
September 27, 2022 - 6 minutes
TILT and MSD working on immunotherapy trial for non-small cell lung cancer
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial…
September 26, 2022 - 3 minutes
Grant awarded to help bring to market an innovative treatment for bone cancer
A grant has been awarded to look into the feasibility of bringing to market a…
September 23, 2022 - 3 minutes
